Home›Trial›NCT06051617
🔬NCT06051617Phase 3RECRUITING

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Study Summary

To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.

Conditions
Primary Biliary Cholangitis
Interventions / Drugs
SeladelparPlacebo
View on ClinicalTrials.gov ↗
Sponsor
GILD
Gilead Sciences
Antiviral
F24/100
Study Details
Enrollment318 participants
Primary Completion—
Lead SponsorGilead Sciences
Data Retrieved2026-04-11 02:55:27.113431+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.